Detalles de la búsqueda
1.
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer.
Oncologist
; 26(2): 139-146, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33145877
2.
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Oncologist
; 24(4): 563-569, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30541754
3.
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
Oncologist
; 22(6): 743-749, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28424325
4.
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.
BJU Int
; 118(4): 590-7, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26780387
5.
U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Oncologist
; 20(8): 960-6, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26070917
6.
Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
Cancer
; 120(19): 3025-32, 2014 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24965506
7.
Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells.
Proc Natl Acad Sci U S A
; 108(29): 11878-83, 2011 Jul 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-21730179
8.
Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma.
Oncologist
; 23(2): 139-142, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29180460
9.
Comparison of Good Clinical Practice Inspection Processes for Marketing Applications Between the United States Food and Drug Administration and the European Medicines Agency.
Ther Innov Regul Sci
; 57(1): 79-85, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35972722
10.
Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency.
Ther Innov Regul Sci
; 56(5): 753-764, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35610469
11.
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.
Clin Cancer Res
; 28(7): 1353-1362, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35031545
12.
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
N Engl J Med
; 365(2): 97-9, 2011 Jul 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-21675880
13.
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
Cancer Invest
; 27(2): 221-6, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19235596
14.
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody.
J Clin Oncol
; 37(30): 2730-2737, 2019 10 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-31116675
15.
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
Oncology (Williston Park)
; 21(12): 1503-8; discussion 1511, 1513, 1516 passim, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-18077994
16.
Correction to: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency.
Ther Innov Regul Sci
; 56(5): 767, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35666455
17.
Publisher Correction: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency.
Ther Innov Regul Sci
; 56(5): 765-766, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35637424
18.
Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: treatments in urologic oncology.
Urol Oncol
; 33(3): 137-42, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25613202
19.
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.
Clin Cancer Res
; 20(19): 4994-5000, 2014 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25096067
20.
Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumab.
Acta Oncol
; 47(8): 1600-1, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18607842